{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:40:07Z","timestamp":1792593607629,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Allergic rhinitis (AR) is a common allergic condition characterized by frequent sneezing, nasal congestion, nasal itching and rhinorrhea. Chinese medicine formula Yu-Ping-Feng Powder with Variation (YPV) is an empirical formula modified from an ancient Chinese medicine formula named Yu-Ping-Feng Powder, which is widely used for the treatment of allergic diseases such as AR and asthma.<\/jats:p>\n <\/jats:sec>\n \n Purpose<\/jats:title>\n To evaluate the efficacy and safety of YPV on AR patients with the lung and spleen Qi deficiency type using a randomized, double-blind, placebo-controlled clinical trial (RCT).<\/jats:p>\n <\/jats:sec>\n \n Study design and methods<\/jats:title>\n Between April 2022 and June 2023, a total of 58 participants were recruited and randomly allocated to receive either YPV (n\u2009=\u200929) or placebo (n\u2009=\u200929) for 8 consecutive weeks. The changes of the Total Nasal Symptom Score (TNSS), and the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) or the Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ) scores at week 8 were used as the primary outcomes. The secondary outcomes included (1) the change of TNSS at weeks 4, 12 and 16; (2) the RQLQ or the PADQLQ scores at weeks 4, 12 and 16; (3) the change of frequency of AR episodes and their severity Visual Analog Scale (VAS) at weeks 4, 8, 12 and 16; (4) the changes of the gut microbiota composition in stool samples at week 8; and (5) adverse events related to the study treatment.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n YPV treatment could significantly improve the RQLQ score in AR patients at weeks 4, 8, 12, and 16 (\n p<\/jats:italic>\n \u2009=\u20090.05,\n p<\/jats:italic>\n \u2009=\u20090.04,\n p<\/jats:italic>\n \u2009=\u20090.04 and\n p<\/jats:italic>\n \u2009=\u20090.03, respectively), when compared with the placebo treatment. However, it did not improve the TNSS score at week 8 in AR patients when compared with the placebo group. In addition, YPV treatment could reduce the VAS score in AR patients at weeks 12 and 16 when compared with the placebo group, although the reductions were not statistically significant (\n p<\/jats:italic>\n \u2009=\u20090.06 and\n p<\/jats:italic>\n \u2009=\u20090.08, respectively). Importantly, no overt adverse effects were observed in both YPV and placebo groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n YPV was well-tolerated and could effectively ameliorate multiple symptoms of AR and improve the quality of life of AR patients after 8-week treatment.<\/jats:p>\n \n Trial registration<\/jats:bold>\n <\/jats:p>\n \n ClinicalTrials.gov, NCT04976023. Registered 26 July 2021,\n https:\/\/clinicaltrials.gov\/study\/NCT04976023?cond=The%20Effects%20of%20Using%20Yupingfeng%20Powder%20with%20Variation%20for%20the%20Treatment%20of%20Allergic%20Rhinitis&rank=2<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1186\/s13020-025-01120-2","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T03:34:43Z","timestamp":1748230483000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploring the efficacy and safety of Yu-Ping-Feng powder with variation against allergic rhinitis: a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"20","author":[{"given":"Zhi-Xiu","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tin Muk","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5032-0366","authenticated-orcid":false,"given":"Yan-Fang","family":"Xian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kam Leung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Qing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho Wing","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin Che Yuen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kam Lun","family":"Hon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin Bond","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chon Pin","family":"Chia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Him","family":"Sum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tak Yee","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui Kuan","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Yuet Ling","family":"Ching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Chun","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Ling","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"issue":"1","key":"1120_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.anai.2018.03.028","volume":"121","author":"MS Blaiss","year":"2018","unstructured":"Blaiss MS, Hammerby E, Robinson S, et al. The burden of allergic rhinitis and allergic rhinoconjunctivitis on adolescents: a literature review. Ann Allergy Asthma Immunol. 2018;121(1):43-52.e3.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1120_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4168\/aair.2016.8.1.49","volume":"8","author":"DH Kim","year":"2016","unstructured":"Kim DH, Han K, Kim SW. Relationship between allergic rhinitis and mental health in the general Korean adult population. Allergy Asthma Immunol Res. 2016;8(1):49\u201354.","journal-title":"Allergy Asthma Immunol Res"},{"issue":"3","key":"1120_CR3","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.anai.2023.10.029","volume":"132","author":"J Zhang","year":"2024","unstructured":"Zhang J, Yang X, Chen G, et al. Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. Ann Allergy Asthma Immunol. 2024;132(3):346-354.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1120_CR4","volume-title":"Allergic rhinitis","author":"S Akhouri","year":"2023","unstructured":"Akhouri S, House SA. Allergic rhinitis. Treasure Island, FL, USA: StatPearls Publishing; 2023."},{"issue":"8","key":"1120_CR5","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/j.jaip.2023.05.016","volume":"11","author":"A Licari","year":"2023","unstructured":"Licari A, Magri P, De Silvestri A, et al. Epidemiology of allergic rhinitis in children: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2023;11(8):2547\u201356.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1120_CR6","first-page":"109","volume":"6","author":"MB Bridgeman","year":"2017","unstructured":"Bridgeman MB. Overcoming barriers to intranasal corticosteroid use in patients with uncontrolled allergic rhinitis. Integr Pharm Res Pract. 2017;6:109\u201319.","journal-title":"Integr Pharm Res Pract"},{"key":"1120_CR7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jaci.2010.06.047","volume":"126","author":"JL Brozek","year":"2010","unstructured":"Brozek JL, Bousquet J, Baena-Cagnani CE, et al. allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466\u201376.","journal-title":"J Allergy Clin Immunol"},{"key":"1120_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1046\/j.1365-2273.2000.00417.x","volume":"25","author":"GK Scadding","year":"2000","unstructured":"Scadding GK, Richards DH, Price MJ. Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. Clin Otolaryngol Allied Sci. 2000;25:551\u20137.","journal-title":"Clin Otolaryngol Allied Sci"},{"issue":"3","key":"1120_CR9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.jaci.2020.07.036","volume":"147","author":"P Demoly","year":"2021","unstructured":"Demoly P, Corren J, Creticos P, et al. A 300 IR sublingual tablet is an effective, safe treatment for house dust mite-induced allergic rhinitis: an international, double-blind, placebo-controlled, randomized phase III clinical trial. J Allergy Clin Immunol. 2021;147(3):1020-1030.e10.","journal-title":"J Allergy Clin Immunol"},{"key":"1120_CR10","first-page":"202","volume":"11","author":"MQ Li","year":"2015","unstructured":"Li MQ. Clinical observation of 117 cases of allergic rhinitis treated with integrative treatment of Chinese and western medicine. Med Inf. 2015;11:202.","journal-title":"Med Inf"},{"key":"1120_CR11","first-page":"18","volume":"261","author":"Z Zhou","year":"2010","unstructured":"Zhou Z, Lu Y. Therapeutic observation of 64 cases of allergic rhinitis treated by integrated Chinese and western medicine. Hunan J Traditional Chin Med. 2010;261:18\u20139.","journal-title":"Hunan J Traditional Chin Med"},{"issue":"4","key":"1120_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ijporl.2015.02.002","volume":"79","author":"HR Yen","year":"2015","unstructured":"Yen HR, Liang KL, Huang TP, et al. Characteristics of traditional Chinese medicine use for children with allergic rhinitis: a nationwide population-based study. Int J Pediatr Otorhinolaryngol. 2015;79(4):591\u20137.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"1","key":"1120_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/1745-6215-15-261","volume":"15","author":"RYP Chan","year":"2014","unstructured":"Chan RYP, Chien WT. The effects of two Chinese herbal medicinal formulae vs. placebo controls for treatment of allergic rhinitis: a randomised controlled trial. Trials. 2014;15(1):261.","journal-title":"Trials"},{"issue":"10","key":"1120_CR14","first-page":"2556","volume":"32","author":"XY Fang","year":"2014","unstructured":"Fang XY, Feng SS, Li Y. Clinical efficacy of Yupingfeng capsule in treatment of allergic rhinitis and its safety evaluation. Chin Arch Trad Chin Med. 2014;32(10):2556\u20138 ((In Chinese)).","journal-title":"Chin Arch Trad Chin Med"},{"key":"1120_CR15","first-page":"702","volume":"17","author":"T Chen","year":"2013","unstructured":"Chen T. Clinical observation on the treatment of allergic rhinitis with integrated Chinese and western medicine. Guide China Med. 2013;17:702\u20133.","journal-title":"Guide China Med"},{"key":"1120_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1142\/S0192415X18500568","volume":"46","author":"HJ Kim","year":"2018","unstructured":"Kim HJ, Nam YR, Nam JH. Flos Magnoliae inhibits chloride secretion via ANO1 inhibition in Calu-3 cells. Am J Chin Med. 2018;46:1079\u201392.","journal-title":"Am J Chin Med"},{"key":"1120_CR17","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1142\/S0192415X19500836","volume":"47","author":"HJ Kim","year":"2019","unstructured":"Kim HJ, Woo J, Nam YR, et al. Flos Magnoliae and its constituent linoleic acid suppress T lymphocyte activation via store-operated calcium entry. Am J Chin Med. 2019;47:1627\u201341.","journal-title":"Am J Chin Med"},{"key":"1120_CR18","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.phymed.2008.04.012","volume":"15","author":"Y Shen","year":"2008","unstructured":"Shen Y, Pang EC, Xue CC, et al. Inhibitions of mast cell-derived histamine release by different Flos Magnoliae species in rat peritoneal mast cells. Phytomedicine. 2008;15:808\u201314.","journal-title":"Phytomedicine"},{"key":"1120_CR19","first-page":"114","volume-title":"An illustrated atlas of commonly used Chinese material medica","author":"QX Zhong","year":"2007","unstructured":"Zhong QX. An illustrated atlas of commonly used Chinese material medica. Beijing: People\u2019s Medical Publishing House Co.; 2007. p. 114\u20135."},{"issue":"03","key":"1120_CR20","first-page":"463","volume":"43","author":"P Yang","year":"2018","unstructured":"Yang P, Zhao XX, Zhang YW. Comparison and review on specifications of fermented Cordyceps sinensis products. China J Chin Materia Med. 2018;43(03):463\u20138 (In Chinese).","journal-title":"China J Chin Materia Med"},{"key":"1120_CR21","first-page":"103","volume-title":"Pharmacopoeia of the People\u2019s Republic of China","author":"Chinese Pharmacopoeia Commission","year":"2020","unstructured":"Chinese Pharmacopoeia Commission. Pharmacopoeia of the People\u2019s Republic of China, vol. 1. Beijing: Chemical Industry Press; 2020. p. 103\u20134."},{"key":"1120_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153453","volume":"82","author":"Y Chen","year":"2021","unstructured":"Chen Y, Xian YF, Loo S, Chan WY, Liu L, Lin ZX. Anti-atopic dermatitis effects of Dictamni Cortex: studies on in vitro and in vivo experimental models. Phytomedicine. 2021;82: 153453.","journal-title":"Phytomedicine"},{"key":"1120_CR23","doi-asserted-by":"publisher","first-page":"1058176","DOI":"10.3389\/fphar.2022.1058176","volume":"13","author":"PK Cheong","year":"2022","unstructured":"Cheong PK, Ho TM, Chan KL, et al. The efficacy and safety of Yupingfeng Powder with variation in the treatment of allergic rhinitis: Study protocol for a randomized, double-blind, placebo-controlled trial. Front Pharmacol. 2022;13:1058176.","journal-title":"Front Pharmacol"},{"key":"1120_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11882-014-0479-8","volume":"14","author":"J Kern","year":"2014","unstructured":"Kern J, Bielory L. Complementary and alternative therapy (CAM) in the treatment of allergic rhinitis. Curr Allergy Asthma Rep. 2014;14:479.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"36","key":"1120_CR25","first-page":"3919","volume":"22","author":"L Wang","year":"2021","unstructured":"Wang L, Zhang M. Research progress on traditional Chinese medicine syndrome types of allergic diseases. CJGMCM. 2021;22(36):3919\u201320.","journal-title":"CJGMCM"},{"issue":"7","key":"1120_CR26","first-page":"1305","volume":"38","author":"ST Liang","year":"2021","unstructured":"Liang ST, Yan Y, Wang S, et al. Investigation of the distribution of traditional chinese medicine syndrome patterns in patients with allergic rhinitis in Guangzhou area. J Guangzhou Uinver Trad Chin Med. 2021;38(7):1305\u20139.","journal-title":"J Guangzhou Uinver Trad Chin Med."},{"key":"1120_CR27","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jaci.2020.07.007","volume":"146","author":"MS Dykewicz","year":"2020","unstructured":"Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. J Allergy Clin Immunol. 2020;146:721\u201367.","journal-title":"J Allergy Clin Immunol"},{"key":"1120_CR28","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/all.12383","volume":"69","author":"O Pfaar","year":"2014","unstructured":"Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69:854\u201367.","journal-title":"Allergy"},{"key":"1120_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/1753465811424425","volume":"6","author":"T Ozdoganoglu","year":"2012","unstructured":"Ozdoganoglu T, Songu M, Inancli HM. Quality of life in allergic rhinitis. Ther Adv Respir Dis. 2012;6:25\u201339.","journal-title":"Ther Adv Respir Dis"},{"key":"1120_CR30","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1067\/mai.2001.115566","volume":"108","author":"EO Meltzer","year":"2001","unstructured":"Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol. 2001;108:S45\u201353.","journal-title":"J Allergy Clin Immunol"},{"key":"1120_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1365-2222.1991.tb00807.x","volume":"21","author":"EF Juniper","year":"1991","unstructured":"Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77\u201383.","journal-title":"Clin Exp Allergy"},{"issue":"20","key":"1120_CR32","doi-asserted-by":"publisher","first-page":"4328","DOI":"10.3390\/nu14204328","volume":"14","author":"A Kaczynska","year":"2022","unstructured":"Kaczynska A, Klosinska M, Chmiel P, et al. The crosstalk between the gut microbiota composition and the clinical course of allergic rhinitis: the use of probiotics, prebiotics and bacterial lysates in the treatment of allergic rhinitis. Nutrients. 2022;14(20):4328.","journal-title":"Nutrients"},{"key":"1120_CR33","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1177\/1945892420920477","volume":"34","author":"X Liu","year":"2020","unstructured":"Liu X, Tao J, Li J, et al. Dysbiosis of fecal microbiota in allergic rhinitis patients. Am J Rhinol Allergy. 2020;34:650\u201360.","journal-title":"Am J Rhinol Allergy"},{"key":"1120_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000510536","volume":"182","author":"AM Watts","year":"2021","unstructured":"Watts AM, West NP, Zhang P, et al. The gut microbiome of adults with allergic rhinitis is characterised by reduced diversity and an altered abundance of key microbial taxa compared to controls. Int Arch Allergy Immunol. 2021;182:94\u2013105.","journal-title":"Int Arch Allergy Immunol"},{"key":"1120_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12934-020-01430-0","volume":"19","author":"L Zhu","year":"2020","unstructured":"Zhu L, Xu F, Wan W, et al. Gut microbial characteristics of adult patients with allergy rhinitis. Microb Cell Fact. 2020;19:171.","journal-title":"Microb Cell Fact"},{"key":"1120_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1399-3038.2004.00156.x","volume":"15","author":"MF Wang","year":"2004","unstructured":"Wang MF, Lin HC, Wang YY, et al. Treatment of perennial allergic rhinitis with lactic acid bacteria. Pediatr Allergy Immunol. 2004;15:152\u20138.","journal-title":"Pediatr Allergy Immunol"},{"key":"1120_CR37","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1399-3038.2005.00284.x","volume":"16","author":"GC Peng","year":"2005","unstructured":"Peng GC, Hsu CH. The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite. Pediatr Allergy Immunol. 2005;16:433\u20138.","journal-title":"Pediatr Allergy Immunol"},{"issue":"5","key":"1120_CR38","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.3390\/nu12051427","volume":"12","author":"MG Kang","year":"2020","unstructured":"Kang MG, Han SW, Kang HR, et al. Probiotic NVP-1703 alleviates allergic rhinitis by inducing IL-10 expression: a four-week clinical trial. Nutrients. 2020;12(5):1427.","journal-title":"Nutrients"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01120-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-025-01120-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-025-01120-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T03:34:46Z","timestamp":1748230486000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-025-01120-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1186\/s13020-025-01120-2","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"27 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics approval for the trial was granted by The Joint Chinese University of Hong Kong-Hospital Authority New Territories East Cluster Clinical Research Ethics Committee (CREC Ref. No.:2021.057-T) prior to the trial commencement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that we have no financial and personal relationships with other people or organizations that can inappropriately influent our work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}